gradient of urea and formamide, stained with ethidium bromide and photographed under UV transillumination. To determine the sensitivity of DGGE in detecting RAP1B mutations, random mutagenesis was performed in RAP1B exons 2 and 3. Two mutated PCR products were obtained both in exon 2. Each mutated plasmid was mixed with nonmutated plasmid at different ratios. DGGE analysis detected mutated DNA when representing as low as 10% of the total studied DNA. Using this technique, we did not detect any mutation in RAP1B genomic DNA in the 56 tested samples. We conclude that RAP1A or RAP1B gene mutation is a rare event in MDS bone marrow cells.
The main activation mechanisms of p21 Ras proteins in human tumors are single amino acid substitutions at amino acid 12 (glycine), 13 (glycine) and 61 (glutamine) that significantly reduce the intrinsic GTPases activity of Ras proteins and create a transforming protein. 8 Genomic DNA was analysed in the 56 patients by heteroduplex high-pressure liquid chromatography (HPLC) under denaturating conditions, as previously described. 2 Abnormal profiles were sequenced to confirm the mutation. We found a mutation in N-RAS or K-RAS at codons 12/13 or 61 in seven of 56 studied patients (12.5%), which is in accordance with previous studies in the literature. These mutations were identified mainly in high-grade MDS, including RAEB and secondary AML.
Deregulation of Rap1 signaling has been identified in malignancies, for example, the Rap1-GEF, CalDAG-GEF, is activated by proviral insertion in a leukemia-prone strain of mice, and the Bcr-Abl fusion tyrosine kinase that plays a central role in chronic myelogenous leukemia, activates both the Ras/ Raf-1 and the Rap1/B-Raf pathways. On the other hand, mutations in RAP1 genes have rarely been investigated in human tumors. In a small series of patients with cold thyroid follicular adenomas, no mutation was identified in either Epac or Rap1. 7 Although RAP1 does not appear as a frequent target for mutagenesis, its activation could participate to malignant phenotype either by activating the B-Raf/MEK/ERK signalling pathway or by stimulating integrin activation and chemokineinduced migration, both favouring hematopoietic cell survival outside of their normal microenvironment in the bone-marrow. Other mechanisms leading to the dysregulated activation of Rap1 could contribute to the pathophysiology of myeloid disorders such as MDS. M Fontenay The finding of extrachromosomal ABL amplifications occurring in T-acute lymphoblastic leukaemia (T-ALL) has been previously reported 1 and further delineated 2 to result in a fusion of NUP214 and ABL1, and this raises the possibility of new therapeutic approaches. It was suggested that 6% of T-ALL patients carry a cryptic NUP214-ABL1 fusion and that the fusion protein acts as a constitutively activated tyrosine kinase similar to the BCR-ABL fusion protein. 2 They also showed that the addition of imatinib, a selective inhibitor of the ABL1 kinase, decreased the phosphorylation of NUP214-ABL1 and of CRKL in cell lines and bone marrow cells from affected individuals and that, as a consequence, these patients may benefit from treatment with imatinib. We would like to report a patient with relapsed T-ALL with episomal amplification of ABL1 who was treated, but failed to respond to imatinib.
The patient, a 42-year-old male presenting with T-ALL, was found to have a karyotype of 45,X,-Y,t(10;14)(q24;q11).
Fluorescence in situ hybridisation (FISH) with the LSI BCR-ABL dual fusion probe (Vysis) was performed after the Leukaemia Research Fund UK Cancer Cytogenetics Group Karyotype Database in Acute Leukemia recommendations 1 and multiple copies of ABL were detected in 96/100 metaphases and interphases (Figure 1 ). During the course of the treatment FISH with BCR-ABL was used to monitor disease progression. The patient entered complete remission following treatment with the MRC UKALLXII protocol with a normal karyotype but relapsed while on maintenance therapy. The relapsed bone marrow on this occasion showed a similar karyotype to the presentation with multiple ABL copies in 46/100 interphases and metaphases. The patient failed to respond to further remission chemotherapy and in view of the cytogenetic findings of ABL amplification the patient was started on imatinib 400 mg daily. A repeat marrow 28 days later showed no bone marrow response with a heavy infiltration by lymphoblasts and the proportion of cells with multiple ABL copies increased to 82/ 100. The patient later underwent a bone marrow transplant but relapsed again after 4 months.
In this case the response to imatinib was disappointing, in fact the proportion of cells with episomal amplification of ABL had increased from 46 to 82%, however; it is possible that higher doses as used in CML blast crisis may have greater efficacy. Furthermore, this patient was treated at relapse and this may have affected the response. The presence of multiple ABL copies results in the amplification of the target kinase and it indicates a poorer prognosis and a rather aggressive course of disease.
1,2 Indeed in Ph þ ALL genomic amplification of the BCR-ABL fusion gene is a recognised mechanism of imatinib resistance. 3 We suggest that clinical studies of treatment with higher dose imatinib in patients with T-ALL and ABL1 amplification in conjunction with chemotherapy and allogeneic transplantation are required, as has produced encouraging results in Ph þ ALL.
